ASH 2024 中国之声 | 77篇口头报告入选，再创历史新高！

英文标题：JAK/Rock Inhibitor Rovadicitinib for Glucocorticoid-Refractory or -Dependent Chronic Graft-Versus-Host Disease: Updated Results of Multicenter, Phase 1b/2a Trial

中文标题：JAK/ROCK抑制剂Rovadicitinib用于糖皮质激素耐药或依赖性慢性移植物抗宿主病：多中心Ib/IIa期试验更新结果

时间：Saturday, December 7, 2024: 9:30 AM

报告人：Yanmin Zhao

英文标题：A Phase II Study to Evaluate the Efficacy and Safety of Pimicotinib (ABSK021) in Chronic Graft Versus Host Disease (cGvHD) after 1 or More Lines of Systemic Treatment

中文标题：一项II期研究，评估Pimicotinib （ABSK021）在1线或多线系统治疗后慢性移植物抗宿主病（cGvHD）中的有效性和安全性

时间：Saturday, December 7, 2024: 10:00 AM

报告人：Depei Wu

英文标题：Multiomic Analyses Uncover Immune Signatures of Steroid-Refractory Graft-Versus-Host Disease

中文标题：多组学分析揭示了类固醇耐药性移植物抗宿主病的免疫特征

时间：Saturday, December 7, 2024: 10:30 AM

报告人：Zengkai Pan

英文标题：Safety and Efficacy of Tgrx-678, a Potent BCR::ABL1 allosteric Inhibitor, in Patients with Tyrosine Kinase Inhibitor Resistant and/or Intolerant Chronic Myeloid Leukemia: Updated Results of Phase 1 Study Tgrx-678 -1001

中文标题：Tgrx-678（一种强效BCR::ABL1变构抑制剂）在酪氨酸激酶抑制剂耐药和/或不耐受的慢性髓系白血病患者中的安全性和有效性：I期研究Tgrx-678 -1001的更新结果

时间：Sunday, December 8, 2024: 10:00 AM

报告人：Qian Jiang

英文标题：Olverembatinib As Second-Line (2L) Therapy in Patients (pts) with Chronic Phase-Chronic Myeloid Leukemia (CP-CML)

中文标题：奥雷巴替尼作为慢性期慢性髓系白血病患者的二线治疗

时间：Sunday, December 8, 2024: 10:45 AM

报告人：Li Weiming

英文标题：Hetrombopag Added to Immunosuppressive Therapy in First-Line Treatment of Severe Aplastic Anemia: A Randomized, Double-Blind, Placebo-Controlled Phase 3 Trial

中文标题：海曲泊帕联合免疫抑制治疗用于重度再生障碍性贫血的一线治疗：一项随机、双盲、安慰剂对照的3期试验

时间：Saturday, December 7, 2024: 4:45 PM

报告人：Fengkui Zhang

英文标题：Safety and Efficacy of Bicistronic CD19/CD22 CAR T Cell Therapy in Childhood B Cell Acute Lymphoblastic Leukemia

中文标题：双顺反子CD19/CD22 CAR T细胞疗法在儿童B细胞急性淋巴细胞白血病中的安全性和有效性研究

时间：Sunday, December 8, 2024: 5:00 PM

报告人：Hua Zhang

英文标题：CD19 CAR T-Cell Therapy in Refractory Autoimmune Hemolytic Anemia

中文标题：CD19 CAR T细胞疗法在难治性自身免疫性溶血性贫血中的应用

时间：Sunday, December 8, 2024: 5:15 PM

报告人：Ruonan Li

英文标题：Sequential Infusion of Anti-CD19 and Anti-BCMA Chimeric Antigen Receptor T-Cells: A Promising Treatment Strategy for Refractory Immune-Mediated Platelet Transfusion Refractoriness

中文标题：序贯输注抗CD19和抗BCMA嵌合抗原受体T细胞：一种治疗难治性免疫介导的血小板输注无效的有前景的治疗策略

时间：Sunday, December 8, 2024: 5:30 PM

报告人：Yunju Ma

英文标题：A Multi-Center Clinical Trial of Allogeneic Hematopoietic Stem Cell Transplants in Transfusion Dependent Thalassemia

中文标题：异基因造血干细胞移植治疗输血依赖性地中海贫血患者的多中心临床试验

时间：Saturday, December 7, 2024: 5:15 PM

报告人：Rongrong Liu

英文标题：Preliminary Efficacy and Safety Results of TQB3473, a Novel Syk Inhibitor, in Adult Patients with Immune Thrombocytopenia (ITP)

中文标题：新型Syk抑制剂TQB3473在成人免疫性血小板减少症（ITP）患者中的初步疗效和安全性结果

时间：Monday, December 9, 2024: 11:00 AM

报告人：Hu Zhou

英文标题：Updated Outcome from Biomarker MSC-C5b-9-Guided All-Trans Retinoic Acid Treatment for Resistant/Recurrent ITP: A Multicenter, Randomized, Open-Label, Phase 3 Clinical Trial

中文标题：生物标志物MSC-C5b-9指导的全反式维甲酸治疗难治性/复发性ITP的更新结果：一项多中心、随机、开放标签的3期临床试验

时间：Monday, December 9, 2024: 11:15 AM

报告人：Menglin Li

英文标题：Decitabine Plus All-Trans Retinoic Acid Versus Decitabine Monotherapy for Myelodysplastic Syndromes with Excess Blasts: A Multicentre, Randomized Controlled Trial

中文标题：地西他滨联合全反式维甲酸对比地西他滨单药治疗骨髓增生异常综合征伴原始细胞增多的一项多中心、随机对照试验

时间：Sunday, December 8, 2024: 5:00 PM

报告人：Hongyan Tong

英文标题：Mini-Dosed Blinatumomab Maintenance Therapy Following Allogeneic Hematopoietic Stem Cell Transplantation in Acute B-Cell Lymphoblastic Leukemia

中文标题：异基因造血干细胞移植后微小剂量贝林妥欧单抗维持治疗在急性B细胞淋巴细胞白血病中的应用

时间：Monday, December 9, 2024: 5:30 PM

报告人：Jie Ji

英文标题：Updated Results from a Phase Ⅱ Clinical Trial：Safety and Efficacy of Azacitidine and Chidamide Maintenance after Allogeneic Hematopoietic Stem Cell Transplantation for Patients with High-Risk Acute Myeloid Leukemia

中文标题：2期临床试验更新结果：阿扎胞苷和西达本胺在高危急性髓系白血病患者异基因造血干细胞移植后维持治疗的安全性和有效性

时间：Monday, December 9, 2024: 5:45 PM

报告人：Rui Huang

英文标题：Rituximab, Lenalidomide, and Zanubrutinib (ZR²) with Sequential CAR-T Cell As First-Line Therapy for High-Risk Large B Cell Lymphoma

中文标题：利妥昔单抗、来那度胺和泽布替尼（ZR2）序贯CAR-T细胞作为高危大B细胞淋巴瘤的一线治疗

时间：Saturday, December 7, 2024: 9:30 AM

报告人：Mingming Zhang

英文标题：IL-10 Expressing CD19 CAR-T Cells Induce Complete Remission and Improve Long-Term Protection in Relapsed or Refractory B-Cell Hematological Malignancies

中文标题：表达IL-10的CD19 CAR-T细胞在复发或难治性B细胞血液恶性肿瘤中诱导完全缓解并改善长期保护作用

时间：Saturday, December 7, 2024: 9:45 AM

报告人：Jingjing Ren

英文标题：A Highly Selective and Orally Bioavailable CK1α Molecular Glue Degrader Targets B-Cell Lymphoma Cells

中文标题：一种高选择性和口服生物可利用的CK1α分子胶降解剂靶向B细胞淋巴瘤细胞

时间：Monday, December 9, 2024: 4:45 PM

报告人：Ran Kong

英文标题：KPT-330 Combined with Radiation Therapy: Effective Central Nervous System Lymphoma Treatment with Reduced Neurotoxicity

中文标题：KPT-330 联合放射治疗：有效降低神经毒性的中枢神经系统淋巴瘤治疗方法

时间：Monday, December 9, 2024: 5:15 PM

报告人：Bingzong Li

英文标题：CD93⁺ Myeloid Cells Suppress T-Cell-Mediated Anti-Tumor Immunity

中文标题：CD93⁺ 髓系细胞抑制 T 细胞介导的抗肿瘤免疫

时间：Monday, December 9, 2024: 5:45 PM

报告人：Hui Yu

英文标题：Venetoclax Combined with Hag Regimen in Newly Diagnosed ETP-ALL: A Prospective, Multicenter, Phase 2 Trial

中文标题：维奈克拉联合HAG方案治疗新诊断ETP-ALL：一项前瞻性、多中心、II期试验

时间：Monday, December 9, 2024: 3:00 PM

报告人：Shanshan Suo

英文标题：Tucidinostat Plus Pediatric-Inspired Chemotherapy As First-Line Therapy for Newly Diagnosed ETP-ALL/Lbl: An Open-Label, Single-Arm, Phase 2 Trial

中文标题：Tucidinostat 联合类似于儿童的化疗作为新诊断ETP-ALL/LBL 的一线治疗：一项开放标签、单臂、II期试验

时间：Monday, December 9, 2024: 3:45 PM

报告人：Jieping Lin